purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation gild earnings call period ending march image source motley fool gilead science gild q earnings callapr pm etcontents prepared remark question answer call participant prepared remark operatorgood afternoon everyone welcome gileads first quarter earnings conference call name rebecca host today moment begin prepared remark qa session operator instruction hand call jacquie ross vp investor relation corporate strategic financejacquie ross vice president investor relation thank rebecca market closed today issued press release earnings result first quarter press release slide supplementary data available investor section website gileadcom speaker today call chairman chief executive officer daniel oday chief commercial officer johanna mercier chief medical officer merdad parsey chief financial officer andrew dickinson open qa team joined cindy perettie executive vice president kite get started let remind making forwardlooking statement please refer slide regarding risk uncertainty relating forwardlooking statement could cause actual result differ materially turn call dandan oday chairman chief executive officer thank jacquie good afternoon everyone want start thanking gilead team delivering strong first quarter see commercial performance clinical execution total product sale excluding veklury grew year year billion driven higher demand across hiv oncology liver disease veklury sale continue track rate hospitalization covid reached total million sale growth quarter reflected diversity portfolio hiv product sale grew year year oncology product sale driven trodelvy well established regimen secondline metastatic triplenegative breast cancer transformative cell therapy outlined recent kite analyst event maryland exciting plan build clear market leadership cell therapy expand community network yous double manufacturing capacity move new indication disease area nextgeneration product eps perspective firstquarter result reflect close cymabay acquisition inquired ip rd charge billion expense per share excluding charge nongaap diluted eps would first quarter expectation driven higher product sale cymabay acquisition brings u important registrational medicine seladelpar potential address significant unmet need liver disease filed regulatory approval seladelpar treatment primary biliary cholangitis pbc fda ema expect fda regulatory decision august approved leverage industryleading commercial infrastructure longstanding expertise liver disease bring seladelpar potentially transformative therapy people pbc might benefit moving clinical execution pleased momentum hiv pipeline reflected data abstract croi based strength data initiated phase trial bictegravir lenacapavir novel oncedaily oral regimen plan advance onceweekly oral program including lenacapavir plus islatravir phase later year host hiv analyst event share detail shape hiv landscape innovative option prevention treatment including next wave longacting therapy pas johanna briefly recap milestone slide already achieved first patient phase artistry artistry trial evaluating oncedaily lenacapavir combination bictegravir well phase first patient swift evaluating g oral alphabeta inhibitor also track upcoming milestone including update three phase clinical trial trodelvy lenacapavir looking ahead rest time focused execution gilead stay disciplined agile approach focus organization nearterm execution longerterm plan clinical program play major patent expiration decade many opportunity growth lot potential lot deliver thanks gilead team great work quarter ongoing progress across diverse portfolio therapy hand johannajohanna mercier chief commercial officer thanks dan good afternoon everyone first quarter marking ninth consecutive quarter yearoveryear growth base business team delivered strong start notably navigating seasonal firstquarter dynamic establishing firm base continue build year beginning slide total product sale excluding veklury billion first quarter year reflecting solid growth hiv oncology liver disease business including veklury total product sale billion year year moving hiv slide sale year year billion primarily driven higher demand well favorable pricing dynamic europe expected repeat quarteroverquarter sale driven typical seasonality experienced first quarter year partially offset higher demand reminder quarterly hiv growth general variable le indicative overall trend full year evident first quarter every year inventory drawdown typically occurs following build generally happens toward end prior year patient copays deductible start every year together shift channel mix lower average realized price first quarter always typically see quarterly pricing inventory dynamic normalize progress throughout year continue expect approximately hiv sale growth supporting outlook treatment market grew line expectation shown slide biktarvy remains leading regimen hiv treatment across major market new start well switching regimen sale year year billion reflecting strong demand quarter quarter sale higher demand offset typical seasonal factor discussed earlier notable six year launch biktarvy continues gain market share yous three percentage point year year approximately share outpacing branded regimen hiv treatment moreover continue see biktarvys benefit extend broader population people hiv recently biktarvy granted fda approval use virologically suppressed individual known suspected resistance common form treatment resistance turning prevention descovy sale year year million driven lower average realized price due channel mix partially offset higher demand sequentially sale reflecting seasonal dynamic discussed earlier partially offset higher demand market volume february temporarily disrupted cyberattack change healthcare volume readily recovered march overall prep market continued demonstrate robust growth first quarter descovy maintaining prep market share yous despite availability regimen including generic solid setup look potentially launch lenacapavir early late next year first twiceyearly subcutaneous prevention option given gileads strong commercial foundation across treatment prevention wellpositioned maintain leadership hiv look evolving marketplace daily oral longacting oral longacting injectables moving liver disease slide sale first quarter million year year primarily driven favorable inventory dynamic timing purchase department correction hcv product well higher demand across hcv hbv hdv sequentially sale primarily reflecting timing hcv purchase despite fewer hcv start globally year year viral hepatitis portfolio overall remained stable continues meaningful contributor commercial performance strength underpinned extensive global footprint expertise treatment liver disease end pending approval gilead excited bring seladelpar patient treatment certain adult pbc impacting approximately people yous people europe sale force cover almost yous prescriber base pbc expect readily make seladelpar available patient upon approval second half year seladelpar demonstrated potential bestinclass differentiated clinical profile existing emerging therapy particularly key symptom disease pruritus following launch expect seladelpar contribute modestly sale meaningfully beyond turning slide veklury continues standard care antiviral hospitalized patient treated covid market share well united state covidrelated hospitalization lower first quarter winter wave peaking earlier expected yous europe compared region japan result veklury sale overall year year sequentially million shifting oncology slide sale year year million firmly billion annual run rate treated patient date look forward bringing portfolio medicine future treatment across line therapy tumor type many patient around world moving slide trodelvy sale first quarter exceeded million year year reflecting continued demand sequentially sale primarily driven demand outside yous well unfavorable fourthquarter pricing dynamic europe repeat partially offset inventory dynamic yous saw drawdown first quarter overall trodelvys strong market share reflects awareness among provider patient secondline metastatic triplenegative breast cancer trodelvy remains leading regimen approximately onethird yous pretreated hrher metastatic breast cancer setting trodelvy demonstrated continued adoption notably ihc setting confident trodelvy continues differentiate safety profile clinically meaningful survival benefit patient across tumor type already treated date look forward potentially extending trodelvys reach many patient year ahead particularly bladder cancer earlierline breast cancer setting lung cancer turning slide behalf cindy kite team cell therapy sale million first quarter year year sequentially sale inline guidance flat slightly pleased see continued demand yescarta tecartus existing new market across europe geography japan seen good progress growing brand share expanding network authorized treatment center date yous consistent recent update see opportunity growth expanding number authorized treatment center affiliated satellite also driving increased referral community setting example proud established flagship community collaboration tennessee oncology first quarter identified many critical learning partner effectively community oncology practice cell therapy continue refine blueprint become efficient onboarding new center time expect start seeing impact initiative toward end wrapping first quarter strong start year primarily driven higher demand across core business year year look forward carrying momentum bring seladelpar market later year following approval would like thank commercial team crossfunctional partner across gilead kite strong execution diligently expand therapy new population positively impacting people around world hand call merdadmerdad parsey chief medical officer thank johanna busy first quarter gilead cadence clinical readout continue throughout rest year importantly anticipate fda regulatory decision seladelpar three phase update across hiv prevention bladder cancer breast cancer starting slide continue progress industryleading virology pipeline building momentum following datarich presence croi march included robust virologic suppression data oncedaily oral combination bictegravir lenacapavir phase portion artistry trial novel combination potential benefit people hiv complex regimen since started two phase trial combination one virologically suppressed individual another virologically suppressed treatmentexperienced individual expect complete enrollment first half also two onceweekly oral program first combination lenacapavir mercks nrtti islatravir virologically suppressed people hiv expected advance phase later year second combination capsid inhibitor g novel oral integrase inhibitor working advance combination phase study second program potential first onceweekly oral regimen containing insti agent instis standardofcare treatment hiv important treatment option clinician continue prefer instibased regimen finally presented phase b data twiceyearly parenteral program lenacapavir plus two broadly neutralizing antibody people hiv croi intend share data phase study second half year moving prep plan share update phase purpose trial second half year data purpose together data purpose expected support filing lenacapavir hiv prevention prep option would offer convenient dosing schedule first twiceyearly subcutaneous regimen could also transformative term adherence hiv prevention regimen turning slide trodelvy program continues evaluated across range solid tumor seven phase trial currently underway across breast bladder metastatic nonsmall cell lung cancer plan start phase trial endometrial cancer later year abstract title released yesterday upcoming asco meeting pleased dozen oncology presentation year presenting latebreaking phase data secondline plus metastatic nonsmall cell lung cancer trial evoke updated data firstline pdl high subject cohort phase evoke trial also shared plan providing update cohort c evaluating trodelvy plus pembro chemotherapy pdl allcomers medical congress second half year addition presentation phase edgegastric trial phase arc study highlighted depending timing event accrual anticipate two phase update year trodelvy include overall survival data confirmatory phase bladder cancer study tropic could support trodelvys submission full regulatory approval yous enable exyous filing tnbc trodelvy adc demonstrated statistically significant improvement overall survival secondline setting expect share update phase ascent trial firstline pdl negative patient later year moving cell therapy pleased share kite approach development novel cell therapy cindy team presented last month investor event see slide yescarta tecartus established kite leader cell therapy plan potentially extend leadership multiple myeloma also paving way innovative nextgeneration construct anitocel laterline multiple myeloma expect provide phase immagine trial update second half year update follows highly encouraging phase data presented ash last year anitocel demonstrated durable response median progressionfree survival yet met month median followup case parkinsonian symptom observed trial nextgeneration cell therapy asset bicistronic optimized manufacturing construct phase trial aimed overcoming resistance mechanism providing potentially deeper sustained response improving product potency beyond early research allogeneic vivo car plan expand range disease area multiple myeloma anitocel solid tumor autoimmune disease moving inflammation slide recently completed acquisition cymabay added seladelpar investigational ppardelta agonist portfolio phase clinical trial seladelpar demonstrated significant improvement pruritus marker cholestasis related risk progression pbc previously announced fda ema accepted regulatory filing seladelpar management pbc certain adult patient anticipate fda regulatory decision august th decision european regulator early next year continue work global regulatory authority expand reach seladelpar pbc patient look rest inflammation pipeline several early phase asset progressed phase trial including potentially firstinclass oral tpl inhibitor potentially bestinclass oral alphabeta antiintegrin oral irak inhibitor wrapping slide continue progress clinical milestone year two first patient one data readout completed first quarter remain ontrack remaining milestone hand call andyandy dickinson chief financial officer thank merdad good afternoon everyone beginning slide strong start year base business year year solid growth achieved across hiv oncology liver disease offset decline veklury total product sale year year billion expected base business quarter quarter primarily driven seasonal inventory pricing dynamic hiv moving beyond revenue result two item significantly impacted eps performance first quarter shown slide first gaap nongaap result included acquired iprd charge billion per share associated close cymabay acquisition asset acquisition transaction fully expensed first quarter nondeductible expense item result impacted effective tax rate excluding expense nongaap eps would first quarter expectation primarily driven higher sale second item shown righthand side impairment charge included gaap result excluded nongaap result reminder relates carrying value iprd indefinitelived intangible asset acquired immunomedics end carrying value billion associated nonsmall cell lung cancer result evoke readout late january reassessed reduced remaining value billion primarily reflects smaller addressable market trodelvy could serve among l metastatic nonsmall cell lung cancer patient delay expected launch timing associated competitive activity remain confident trodelvy deliver attractive return time sale exceeding billion year strong ip portfolio development program multiple shotsongoal new indication well earlierlines therapy including opportunity included initial deal model meantime see impairment impacted firstquarter gaap eps per share moving rest nongaap result slide first quarter product gross margin modestly primarily due product mix rd sga year year second consecutive quarter operating expense decline yearoveryear basis reflecting continued focus disciplined expense management effective tax rate first quarter negative reflecting nondeductibility cymabay acquired iprd charge overall diluted earnings per share negative compared positive period last year primarily reflecting per share expense related cymabay acquisition switching fullyear guidance slide change revenue expectation time continue expect total product sale range billion continue expect total product sale excluding veklury range billion representing growth base business year year additionally change veklury guidance approximately billion full year discussed last quarter expect update veklury guidance thirdquarter earnings call absent clear trend covid infection shifting part pl nongaap basis change gross margin guidance continue expect product gross margin range expect rd grow higher end previous lowtomid singledigit growth range reflecting incremental expense associated cymabay acquisition continue expect sga expense decline midsingledigit percentage relative dollar basis sga expected modestly higher previous sga expectation incorporate cymabay expense however manage within window previously issued operating expense guidance acquired iprd expected approximately b due cymabay transaction well milestone anticipated throughout rest year operating income expected range billion billion reflecting updated acquired iprd guidance modest increase operating expense associated cymabay transaction given nondeductible impact cymabay acquisition effective tax rate expected approximately includes negative impact approximately onetime charge acquisition cymabay therefore expect diluted eps range shown slide updated reflect transaction closed first quarter excluding charge see comfortably within range eps guidance shared back early february gaap basis expect fullyear diluted eps range moving slide capital allocation priority remain unchanged sufficient flexibility balance sheet specifically demonstrated first quarter announced increase quarterly dividend returned approximately billion shareholder addition acquired cymabay billion adding seladelpar portfolio overall continue disciplined use capital continue flexible opportunistic unlikely gilead engaging sizable transaction near term wrap slide quick note expectation cymabay transaction closed pending regulatory approval expect launch seladelpar yous end johanna highlighted earlier modest revenue contribution expected year additionally shared transaction expected add operating expense year make incremental investment support launch well rd effort able manage within window previously issued operating expense guidance look ahead transaction dilutive eps year expect deal breakeven earnings significantly accretive onwards invite rebecca begin qa question answer operatorthank andy time open call question ask courteous limit one question get many analyst possible today call operator instruction first question come chris schott jpmorgan chris go ahead line openchris schott jpmorgan chase company analyst great thanks much question question hiv franchise impact medicare redesign think know coming conversation talk little bit thinking impact franchise maybe broadly directionally still think topline growth margin expansion gilead next year despite headwind color provide would appreciated thank youdan oday chairman chief executive officer yeah great chris welcome everybody dan going johanna cover question thank youjohanna mercier chief commercial officer thanks chris question expect impact part redesign weighted toward hiv business expect hiv growth offset part redesign impact result expect hiv sale roughly flat year year said overall expect total business grow despite impact part designed top line building momentum beyond right beyond expect growth hiv business demand hiv offset impact part dandy dickinson chief financial officer chris andy take question margin expansion know provide specific guidance beyond johanna mentioned said historically underscored focused disciplined expense management true today seen last two quarter think nongaap basis quarter look operating margin strip cymabay transaction see improvement operating margin expect continue time expect broadly operating margin improve time see continued topline growth disciplined expense management thanks question detail course provided early next year provide guidance specificallyoperatorour next question come daina graybosch leerink partner daina line opendaina graybosch leerink partner analyst great thanks question kite fda odac recently two important meeting relevance multiple myeloma cart one dealt early death risk carvykti abecma second recommend mrd intermediate endpoint accelerated approval multiple myeloma wonder thinking odacs relation anitocel earlier line trial design thank youdan oday chairman chief executive officer thanks daina got cindy perettie go right hercindy perettie executive vice president kite thanks daina start early line odac think believe positive everybody shown people recognize value car t therapy earlier disease value diseasefree interval get happy see think equally excited see second odac around mrd minimal residual disease secondary additional endpoint think piece around really encouraged odac decision going open door u potentially bring anitocel market faster patient process right understanding mrd surrogate endpoint used regulatory agency application program come frontoperatorour next question come umer raffat evercore isi umer line openumer raffat evercore isi analyst hi guy thanks taking question thought spend quick second cymabay given recent deal question gilead diligence process deploy independent pathologist evaluate case possible liver pathology happened nash trial previously well paired liver biopsy data pbc trial lower dose cymabay think would need safety adjudication would curious guy would ever publish thank youdan oday chairman chief executive officer merdad let answer merdad parsey chief medical officer thanks umer let start saying think seladelpar one medicine bring lot benefit patient really nearterm expansion liver portfolio think synergize many much work liver disease overall obviously thorough diligence approach seladelpar cymabay third think question around whether independent thirdparty review pathology however lot thorough diligence data outcome confident around outcome mean patient time obviously waiting right upcoming pdufa date also file ema optimistic following question sort item looking forward providing update filing proceedoperatorour next question come tyler van buren td cowen tyler line opentyler van buren td cowen analyst hey guy good afternoon thanks much question hoping could help set expectation evoke presentation asco evoke late breaker tag interesting related month o benefit pd refractory patient could expecting something evoke hope see cohort data leave u confident evoke readout next yearmerdad parsey chief medical officer thanks tyler merdad little challenging share many detail embargo obviously happy fill lot blank data released talk asco think evoke think number pipeline update asco presentation upcoming see real change u real evolution pipeline overall ability build oncology pipeline bring new option patient part late breaker session evoke mentioned include data overall survival pfs orr duration response well safety profile course wish could give detail point say also providing update including evoke cohort data looking pdl high nonsmall cell population really talk detail data looking forward sharing result everyone talking implication broader lung cancer especially frontline lung cancer evoke study conducting right underway partner merckoperatorour next question come line geoff meacham bank america geoff line opengeoff meacham bank america merrill lynch analyst good afternoon everyone thanks question merdad question cell therapy front usually anitocel update later year big beyond sure priority among nextgen car asset got kind cartooned slide lot competition space guy among player real scale could move nextgen stuff think pretty fast pick sort priority list good know thank youdan oday chairman chief executive officer thanks geoff dan going cindy perettie answer question mind cindy youcindy perettie executive vice president kite hi geoff three product right three construct phase b clinical trial first one bicistronic cd cd bb cd second one construct fast manufacturing day manufacturing one cd like yescarta threeday manufacturing looking three parallel goal picking winner advance rapidly pivotal trial coming next obviously shared lot around anitocel well anitocel immagine readout expect move quickly earlier line relates anitocel hear later year hopefully answer question certainly number play early research would plan advance nextgeneration lymphoma asset quickly obviously scale kite well integrated fact create vector well construct inhouse operatorour next question come michael yee jefferies michael go ahead line openmichael yee jefferies analyst hi guy thanks following trodelvy data coming asco enthusiasm frontline remind u believe data evoke second line asco least competitive better astra excited frontline b triple therapy top chemo combo whole firstline strategy top pd thank youmerdad parsey chief medical officer thanks michael merdad noted think talked evoke data second line something discus asco show data full data set motivate u go forward lung cancer including discussion regulator unmet need population great data give u option including discussion health authority conducting followup trial able share data provided asco look forward deeper discussion speak directly data sorry second part question around front line think able share evoke data update evoke data able talk continue allow u think frontline confidence around evoke last part question combination think intraportfolio combination example combination dambinelumab trodelvy trial looking see get additional efficacy sort combination continuously look portfolio look opportunity moving needle combination within portfoliooperatorour next question come salveen richter goldman sachs salveen go ahead line opensalveen richter goldman sachs analyst good afternoon thanks taking question currently billion cash noted leverage back preimmunomedics deal level thinking meaningful bolton bd post cymabay acquisition preference virology ii oncology thank youandy dickinson chief financial officer hey salveen andy maybe start one prepared remark highlighted near term expect sizable lot execution ahead u deep portfolio lot growth driver including seladelpar clearly highlighting short term continue ordinary course business development standard licensing deal saw couple first quarter unlikely would pursue meaningful near term also said historically deal like cymabay exactly looking deal like regular basis cycle whether every two year average le general ballpark think appropriately highlighting generate lot operating cash flow saw first quarter rebuild cash time going continue invest pipeline least short run expect meaningful short rundan oday chairman chief executive officer salveen dan answer end question mean always therapeutic area agnostic approach mean first got robust portfolio around urology oncology building portfolio inflammation look frankly across spectrum seladelpar great example finding opportunity within liver disease franchise able use channel equally look opportunity synergy complement portfolio across therapeutic area approach think make sense look attractive science andy said lot hand work execute keep bar highoperatorour next question come james shin deutsche bank james line openjames shin deutsche bank analyst hi thanks question wanted ask trodelvys effort hrher destinybreast going data pretty soon seems also ascent sort sound similar destinybreast versus tropic share like think landscape play two trialsmerdad parsey chief medical officer thanks question james well learned try keep away prognostication harder look maybe way would put proud fact trodelvy still trop adc approved large part driven important role trodelvy play breast cancer right patient continue want push along ascent number trial ongoing expand footprint breast cancer think right tnbc leading regimen continuing advance hrher particular ihc population think remain confident around place shown benefit randomized clinical trial basis regulatory filing approval think assume success see data looking forward year coming ascent coming think provide u additional information expand potential breast cancer johanna want addjohanna mercier chief commercial officer maybe add would also say option patient woman hr earlier line therapy instead cycling chemotherapy better db result moving potentially compound earlier actually allows trodelvy also play important bigger population today profile tropic label believe opportunity adc move also differentiate versus adcs marketplace depends effect profile safety profile efficacy light ihc setting really strong foothold hrher believe continue whether later line therapy earlier line study play outoperatorour next question come mohit bansal well fargo mohit go ahead line openmohit bansal well fargo security analyst great thank much taking question maybe big picture question think medium longer term mean yes loe mean hiv growth somewhere around low single digit oncology mean mean dropped expansion opportunity seem limited point trying understand turn low singledigit like high singledigit kind growth overall company cymabay definitely addition thinking medium long term probably people like u missingdan oday chairman chief executive officer mohit maybe start others add first think stepping back thinking portfolio built past four year doubling size portfolio significant advance hiv portfolio oncology outside cell therapy think growth moving forward mean first would say hiv side business constantly remind others addition treatment market potential longacting treatment robust program update little bit toward second half year analyst event got prep market beginning kind dimensionalized think provides significant growth opportunity think time frame mentioned end decade think allows u think accelerated hiv total growth prevention treatment head toward second half decade top entirety oncology portfolio cell therapy within large bcell lymphoma area well potentially multiple myeloma entry anitocel top robust oncology portfolio trodelvy novel agent read course decade remind got close readout year three phase including lenacapavir prep second half year two trodelvy phase readout importantly added seladelpar mix pdufa date august finally opportunity update anitocel end year well providing guidance continue look entirety portfolio really think within company today way mention addition complementing needed outside within company today take drive substantial growth business course next decade focus expense management well produce good return investorsoperatorour next question come simon baker redburn atlantic go ahead simon line opensimon baker redburn atlantic analyst thank taking question one seladelpar may question really around competitive dynamic launch go according plan launch august ipsen launch elafibranor june wondering really make difference obviously got far greater infrastructure ipsen early steal march paradoxically thus somebody else market promoting pbc actually raise disease awareness help situation color around dynamic launch would helpful thank youjohanna mercier chief commercial officer thanks simon johanna let take one think absolutely right think fact one competitor hitting market great patient namely around increasing disease awareness around pdc fact two option available said also feel incredibly confident seladelpar well differentiated potentially best disease think significant impact clinically meaningful impact alp normalization clinical jet phase clinical trial seen well improvement pruritus key symptom disease today really effective antipruritic option pbc patient put together addition fact believe footprint commercial medical incredibly well established come liver disease already cover yous pbc prescribers strong differentiated profile referring think three month make difference think really bestinclass launch potential seladelpar look forward pdufa dateoperatorour next question come brian skorney baird brian go ahead line openunknown speaker hi thanks taking question charlie brian ask something seladelpar wondering ambition potentially looking label first line future considering lot unmet need pruritus well potential synergy may considering remainder liver portfolio thank youmerdad parsey chief medical officer thanks charlie merdad frontline challenge given currently background standard care know think seladelpar going bring lot benefit lot patient especially given pruritus potential getting patient earlier course really important u see market start respond presence seladelpar second line recall think thing recall think long people actually get frontline therapy moving secondline therapy given efficacy profile frontline therapy fact option one could anticipate patient moved secondline therapy relatively early treatment course making moving formally registrational trial frontline potentially superfluous think see play market see label sort thing able update thatoperatorour next question come brian abraham rbc capital market brian go ahead line openbrian abraham rbc capital market analyst hi good afternoon thanks much taking question purpose obviously upcoming readout wanted clarify element unique design specifically sensitivity assessing hiv infection occurred accurately project control infection rate control potential intrinsic difference risk behavior screenedout group serving control may versus individual make trial thanksmerdad parsey chief medical officer brian thanks merdad could talk long time let try give concise answer recency assay developed hiv studied thoroughly based diagnosis time screening create profile anyone potentially hiv infected time recently infected think key part relates second part question sense need compare risk behavior randomization looking overall incidence hiv time screening comparing counterfactual design happens people start therapy think two element discussion regulator expert field confident design provide information necessary get u approval adoptionoperatorour next question come terence flynn morgan stanley terence go ahead line openterence flynn morgan stanley analyst great thanks taking question two part cart franchise wondering high level comment anitocel prof parkinsonism meaning le differentiated second part curious progress stand respect developing cart immunology obviously lot focus among number company industry curious gileads thought forward thank youcindy perettie executive vice president kite thanks terence question commitment anitocel relates parkinson absolutely feel differentiated potentially safety efficacy noted earlier observed neurotox construct observed continue monitor feel great profile right efficacy profile early signal think equivalent could bestinclass behind anitocel looking forward bringing data soon second question around autoimmune space continue monitor autoimmune space heard andy others play space taking time take look space versus portfolio update todayoperatorour last question come carter gould barclays carter go ahead line opencarter gould barclays analyst great good afternoon thanks squeezing maybe round thing cell therapy flagged dynamic kind persisting yous far constraint atcs also saw tennessee oncology reference guess putting together level confidence sort hit return meaningful growth second half year hear mentioned clearly point focus commentary would appreciatedcindy perettie executive vice president kite yeah feel confident going return growth second half year stated think reminder shared quarter guidance would flat slightly quarter part due restructure putting strategy play feel confident approach taking yous looking almost fully stacked sale team back working hard think piece need talk well market dynamic thing observing observing outofclass competition bispecifics atc constraint spoken past based multiple myeloma construct coming seeing lot hospital atcs working constraint feel really confident second half yeardan oday chairman chief executive officer thank cindy dan appreciate joining maybe bit summary statement want know gilead focused nearterm execution longterm plan continue stay disciplined agile approach highlight got active clinical program major patent expiry end decade variety opportunity growth lot deliver top track provide update three phase clinical trial trodelvy lenacapavir got seladelpar pdufa date august update anitocel phase update management end year rest assured firmly focused many opportunity lot potential deliver hand jacquie closing commentsjacquie ross vice president investor relation thank dan close one housekeeping item share tentatively planning release second quarter earnings result thursday august please note date provisional could changed accommodate scheduling conflict arise always announce confirmed date following close second quarter appreciate continued interest gilead look forward updating progress throughout quarter close call today thank duration minutescall participantsjacquie ross vice president investor relationsdan oday chairman chief executive officerjohanna mercier chief commercial officermerdad parsey chief medical officerandy dickinson chief financial officerchris schott jpmorgan chase company analystdaina graybosch leerink partner analystcindy perettie executive vice president kiteumer raffat evercore isi analysttyler van buren td cowen analystgeoff meacham bank america merrill lynch analystmichael yee jefferies analystsalveen richter goldman sachs analystjames shin deutsche bank analystmohit bansal well fargo security analystsimon baker redburn atlantic analystunknown speakerbrian abraham rbc capital market analystterence flynn morgan stanley analystcarter gould barclays analyst gild analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends gilead science motley fool disclosure policy